NasdaqGS:NBIS
NasdaqGS:NBISSoftware

US Stock Market Today: S&P 500 Futures Steady as Rate Cut Hopes Offset Factory Gloom

The Morning Bull - US Market Morning Update Tuesday, Dec, 2 2025 US stock futures are pointing slightly higher this morning, with the S&P 500 expected to open up by around 0.01%. The biggest force driving sentiment right now is the steady yield on 10-year US government bonds, hovering near 4.04%. This means borrowing rates for everything from mortgages to business loans are staying elevated, a direct result of global worries about interest rates and the possibility that the Federal Reserve...
NYSE:DTM
NYSE:DTMOil and Gas

What DT Midstream (DTM)'s Upgraded 2025 Cash Flow Outlook Means for Shareholders

DT Midstream recently lifted its distributable cash flow guidance for 2025 following in-line third-quarter earnings, attributing stronger projections to lower maintenance costs, reduced interest expenses, and lighter cash taxes. The company also reaffirmed its intention to grow its dividend by 5% to 7% annually, maintaining a steady payout and signaling ongoing confidence in future cash flows. We’ll consider how the improved distributable cash flow outlook strengthens DT Midstream’s...
NasdaqGS:IQ
NasdaqGS:IQEntertainment

iQIYI (NasdaqGS:IQ): Assessing Valuation After Revenue Drop and Return to Net Loss

iQIYI (NasdaqGS:IQ) announced third quarter results showing a decline in revenue from last year and a net loss. This marks a reversal from the company’s previous profitability. Investors are weighing the implications for future growth and stability. See our latest analysis for iQIYI. After peaking earlier in the year, iQIYI’s share price momentum has been fading, with a 9.5% drop over the past month and a 22.9% decline in the last quarter. The company’s one-year total shareholder return of...
NasdaqCM:MBIN
NasdaqCM:MBINDiversified Financial

How Investors May Respond To Merchants Bancorp (MBIN) CEO Insider Sale and Dividend Actions

Merchants Bancorp recently announced dividends on its common stock and multiple preferred stock series, while Michael F. Petrie, Chairman and CEO, sold 2,177 Series C Depositary Shares after the Q3 2025 earnings report showed mixed results, including improved asset quality. Petrie's insider sales and ongoing substantial ownership highlight executive confidence and raise questions about leadership sentiment amid ongoing strategic initiatives. We'll explore how recent insider sales by the CEO...
NasdaqGM:HROW
NasdaqGM:HROWPharmaceuticals

Should Vevye’s CVS Formulary Win Prompt a Closer Look from Harrow (HROW) Investors?

Harrow, Inc. recently presented at major industry events and secured a key win as its dry eye therapy Vevye replaced Xiidra on the CVS Tier 1 formulary. This change gives Vevye first-line access at the largest pharmacy benefit manager in the US, which could significantly broaden adoption of Harrow’s flagship product. We’ll explore how Vevye’s elevated CVS formulary status may influence Harrow’s growth profile and long-term investment outlook. Rare earth metals are an input to most high-tech...
NasdaqGM:JFIN
NasdaqGM:JFINConsumer Finance

Jiayin Group (JFIN) Reports Higher Net Income but What Drives Its Sustained Momentum?

Jiayin Group Inc. recently reported its third quarter and nine-month 2025 financial results, with revenue reaching CNY 1.47 billion and CNY 5.13 billion, and net income of CNY 376.49 million and CNY 1.44 billion, respectively, both rising compared to the prior year. The company’s basic earnings per share from continuing operations also showed a clear increase for both the quarter and the year-to-date period. We'll take a look at how Jiayin Group's higher net income growth this quarter...
NasdaqGS:ALKS
NasdaqGS:ALKSBiotechs

Should Strong Q3 Results and Raised 2025 Guidance Require Action From Alkermes (ALKS) Investors?

In the third quarter of 2025, Alkermes reported earnings from continuing operations of US$0.49 per share, surpassing expectations as its proprietary products portfolio saw sales rise 16% year over year, driven by demand for Vivitrol, Aristada, and Lybalvi. The company raised its full-year 2025 revenue guidance to a range of US$1.43 billion to US$1.49 billion, highlighting confidence in continued product demand and business momentum. We'll examine how Alkermes' stronger earnings and upgraded...
NasdaqGS:MGEE
NasdaqGS:MGEEElectric Utilities

Is MGE Energy (MGEE) Overvalued or Undervalued? Evaluating the Latest Valuation Signals

MGE Energy (MGEE) shares slipped slightly over the past week, continuing a downward trend that has stretched across several months. Even with recent earnings growth, investors seem unimpressed as the stock has lost 14% year-to-date. See our latest analysis for MGE Energy. This latest drop brings MGE Energy’s share price return for the year to a challenging -13.8%, reflecting fading investor momentum despite steady earnings growth and broader sector shifts. Looking at a longer timeframe, the...